US52490G1022
US52490G1022
Legend Biotech Corporation
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 3.62B EUR | 11.19B EUR | 6.72B EUR | 8.04B EUR |
Enterprise Value | 2.94B EUR | 10.8B EUR | 6.46B EUR | 7.55B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 17.73x | -- | -- | -- |
Price to Sales | 2.85x | 8.8x | 5.9x | 9.64x |
Price to Book | 2.93x | 9.1x | 6.94x | 8.02x |
EV/Revenue | 2.31x | 8.49x | 5.67x | 9.06x |
EV/EBITDA | -70.65x | 481.86x | -- | -- |
Price to FCF (P/FCF) | 133.17x | -- | -- | -- |
EV/FCF | 108.08x | -- | -- | -- |
FCF Yield | 0.75% | -1.09% | -1.72% | -0.29% |